This is a Validated Antibody Database (VAD) review about human DR5, based on 35 published articles (read how Labome selects the articles), using DR5 antibody in all methods. It is aimed to help Labome visitors find the most suited DR5 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
DR5 synonym: CD262; DR5; KILLER; KILLER/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9; tumor necrosis factor receptor superfamily member 10B; Fas-like protein; TNF-related apoptosis-inducing ligand receptor 2; apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; p53-regulated DNA damage-inducible cell death receptor(killer); tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9

Knockout validation
Cell Signaling Technology
rabbit monoclonal (D4E9)
  • western blot knockout validation; human; 1:1000; loading ...; fig 9e
  • immunocytochemistry; human; 1:200; loading ...; fig 2f
Cell Signaling Technology DR5 antibody (Cell Signaling, D4E9) was used in western blot knockout validation on human samples at 1:1000 (fig 9e) and in immunocytochemistry on human samples at 1:200 (fig 2f). Mol Cell Biol (2017) ncbi
EMD Millipore
rabbit polyclonal
  • western blot knockout validation; human; loading ...; fig 3
EMD Millipore DR5 antibody (Millipore, AB16942) was used in western blot knockout validation on human samples (fig 3). Oncotarget (2017) ncbi
R&D Systems
mouse monoclonal (71903)
  • flow cytometry; human; loading ...; fig s7b
R&D Systems DR5 antibody (R&D, mab631) was used in flow cytometry on human samples (fig s7b). Cell (2019) ncbi
mouse monoclonal (71908)
  • flow cytometry; human; loading ...; fig 5i
R&D Systems DR5 antibody (R&D Systems, FAB6311P) was used in flow cytometry on human samples (fig 5i). Mol Cancer Res (2017) ncbi
mouse monoclonal (71908)
  • flow cytometry; human; fig st1
In order to find cell-surface markers specific to human neutrophils, R&D Systems DR5 antibody (R&D Systems, FAB6311P) was used in flow cytometry on human samples (fig st1). Exp Cell Res (2016) ncbi
goat polyclonal
  • western blot; human; fig 3
R&D Systems DR5 antibody (R&D Systems, AF631) was used in western blot on human samples (fig 3). Hum Exp Toxicol (2015) ncbi
mouse monoclonal (71908)
  • immunohistochemistry - paraffin section; human
R&D Systems DR5 antibody (R&D Systems, MAB6311) was used in immunohistochemistry - paraffin section on human samples . Clin Breast Cancer (2015) ncbi
goat polyclonal
  • immunoprecipitation; human
R&D Systems DR5 antibody (R&D Systems, AF631) was used in immunoprecipitation on human samples . Cell Death Dis (2014) ncbi
mouse monoclonal (71908)
  • flow cytometry; human; 5 ug/ml
R&D Systems DR5 antibody (R&D Systems, 71908) was used in flow cytometry on human samples at 5 ug/ml. J Biol Chem (2011) ncbi
Invitrogen
mouse monoclonal (DJR2-4 (7-8))
  • flow cytometry; human; fig 4c
Invitrogen DR5 antibody (eBioscience, 12-9908-41) was used in flow cytometry on human samples (fig 4c). Cell Death Differ (2019) ncbi
mouse monoclonal (DJR2-4 (7-8))
  • flow cytometry; human; fig s2
Invitrogen DR5 antibody (eBioscience, DJR2-4) was used in flow cytometry on human samples (fig s2). BMC Biotechnol (2016) ncbi
Santa Cruz Biotechnology
mouse monoclonal (D-6)
  • western blot; human; loading ...; fig 1c
Santa Cruz Biotechnology DR5 antibody (Santa Cruz, sc-166624) was used in western blot on human samples (fig 1c). J Biol Chem (2019) ncbi
mouse monoclonal (D-6)
  • immunocytochemistry; human; 1:200
Santa Cruz Biotechnology DR5 antibody (Santa Cruz Biotechnology, SC-166624) was used in immunocytochemistry on human samples at 1:200. Anticancer Drugs (2014) ncbi
mouse monoclonal (B-D37)
  • western blot; human
Santa Cruz Biotechnology DR5 antibody (Santa Cruz Biotechnology, B-D37) was used in western blot on human samples . J Biol Chem (2011) ncbi
Abcam
mouse monoclonal (DR5-01-1)
  • flow cytometry; human; loading ...; fig s5b
Abcam DR5 antibody (Abcam, ab53319) was used in flow cytometry on human samples (fig s5b). Cell (2019) ncbi
Enzo Life Sciences
mouse monoclonal (DJR2-4)
  • flow cytometry; human; 1:100; loading ...; fig 1
Enzo Life Sciences DR5 antibody (Enzo life sciences, ALX-804-914-0100) was used in flow cytometry on human samples at 1:100 (fig 1). Oncotarget (2016) ncbi
goat polyclonal
  • western blot; human
Enzo Life Sciences DR5 antibody (Alexis, ALX-210-743-c200) was used in western blot on human samples . Br J Cancer (2013) ncbi
goat polyclonal
  • immunohistochemistry - paraffin section; human
Enzo Life Sciences DR5 antibody (Enzo Life Sciences, ALX-210-743-C200) was used in immunohistochemistry - paraffin section on human samples . Oncotarget (2012) ncbi
goat polyclonal
  • immunohistochemistry; human; 1:50
Enzo Life Sciences DR5 antibody (Alexis Biochemicals, ALX-210-743-C200) was used in immunohistochemistry on human samples at 1:50. Head Neck (2011) ncbi
BioLegend
mouse monoclonal (DJR2-4 (7-8))
  • other; human; 500 ug/ml; fig 1
BioLegend DR5 antibody (BioLegend, 307402) was used in other on human samples at 500 ug/ml (fig 1). J Extracell Vesicles (2016) ncbi
mouse monoclonal (DJR2-4 (7-8))
  • flow cytometry; human; fig 4
BioLegend DR5 antibody (BioLegend, 307405) was used in flow cytometry on human samples (fig 4). PLoS ONE (2015) ncbi
mouse monoclonal (DJR2-4 (7-8))
  • flow cytometry; human
BioLegend DR5 antibody (Biolegend, DJR2-4) was used in flow cytometry on human samples . Clin Cancer Res (2014) ncbi
Proteintech Group
rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 3d
Proteintech Group DR5 antibody (Proteintech, 15497-1-AP) was used in western blot on human samples at 1:1000 (fig 3d). Biochem Biophys Res Commun (2019) ncbi
Cell Signaling Technology
rabbit monoclonal (D4E9)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology DR5 antibody (Cell Signaling Technology, 8074) was used in western blot on human samples (fig 2a). Sci Rep (2017) ncbi
rabbit polyclonal
  • western blot; human; loading ...; fig 2b
Cell Signaling Technology DR5 antibody (cell signalling, 3696) was used in western blot on human samples (fig 2b). EMBO J (2017) ncbi
rabbit monoclonal (D4E9)
  • western blot knockout validation; human; 1:1000; loading ...; fig 9e
  • immunocytochemistry; human; 1:200; loading ...; fig 2f
Cell Signaling Technology DR5 antibody (Cell Signaling, D4E9) was used in western blot knockout validation on human samples at 1:1000 (fig 9e) and in immunocytochemistry on human samples at 1:200 (fig 2f). Mol Cell Biol (2017) ncbi
rabbit polyclonal
  • western blot; human; loading ...; fig s1
In order to test if TRAIL/TRAIL-R signaling in cancer cells alters the immune microenvironment, Cell Signaling Technology DR5 antibody (cell signalling, 3696) was used in western blot on human samples (fig s1). Mol Cell (2017) ncbi
rabbit monoclonal (D4E9)
  • western blot; human; fig 3a
In order to report that cathepsin S inhibition sensitizes cancer cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis, Cell Signaling Technology DR5 antibody (Cell Signaling, 8074S) was used in western blot on human samples (fig 3a). Antioxid Redox Signal (2017) ncbi
rabbit monoclonal (D4E9)
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology DR5 antibody (Cell Signaling, 8074) was used in western blot on human samples (fig 2a). Int J Biochem Cell Biol (2017) ncbi
rabbit polyclonal
  • western blot; human; fig 2
In order to elucidate the deubiquitinase inhibitor PR-619 and how it sensitizes normal human fibroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death, Cell Signaling Technology DR5 antibody (Cell Signaling, 3696) was used in western blot on human samples (fig 2). J Biol Chem (2016) ncbi
rabbit polyclonal
  • western blot; human; fig s3
Cell Signaling Technology DR5 antibody (Cell Signaling, 3696) was used in western blot on human samples (fig s3). Oncotarget (2015) ncbi
rabbit monoclonal (D4E9)
  • western blot; rat
  • immunocytochemistry; human
Cell Signaling Technology DR5 antibody (Cell Signaling, 8074) was used in western blot on rat samples and in immunocytochemistry on human samples . Toxicol Lett (2015) ncbi
EMD Millipore
rabbit polyclonal
  • western blot knockout validation; human; loading ...; fig 3
EMD Millipore DR5 antibody (Millipore, AB16942) was used in western blot knockout validation on human samples (fig 3). Oncotarget (2017) ncbi
mouse monoclonal (YM366)
  • flow cytometry; human; fig 3
EMD Millipore DR5 antibody (Millipore, MAB10418) was used in flow cytometry on human samples (fig 3). Oncol Lett (2016) ncbi
rabbit polyclonal
  • western blot; human; fig 1
EMD Millipore DR5 antibody (Chemicon, AB16942) was used in western blot on human samples (fig 1). Cell Death Dis (2015) ncbi
ProSci
rabbit polyclonal
  • flow cytometry; human
  • western blot; human
ProSci DR5 antibody (ProSci Inc., 2019) was used in flow cytometry on human samples and in western blot on human samples . J Biol Chem (2013) ncbi
rabbit polyclonal
  • western blot; human
ProSci DR5 antibody (Prosci Inc., 2019) was used in western blot on human samples . Mol Cancer Res (2012) ncbi
rabbit polyclonal
  • western blot; human
ProSci DR5 antibody (ProSci Incorporated, 2019) was used in western blot on human samples . Cell Death Differ (2010) ncbi
rabbit polyclonal
  • western blot; human
ProSci DR5 antibody (ProSci, 2019) was used in western blot on human samples . J Neurooncol (2010) ncbi
Articles Reviewed
  1. Poondla N, Chandrasekaran A, Heese K, Kim K, Ramakrishna S. CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis. Biochem Biophys Res Commun. 2019;: pubmed publisher
  2. Pan L, Fu T, Zhao W, Zhao L, Chen W, Qiu C, et al. Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling. Cell. 2019;176:1477-1489.e14 pubmed publisher
  3. Kim M, Song J, Koh D, Kim J, Hatano M, Jeon B, et al. Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression. J Biol Chem. 2019;294:299-313 pubmed publisher
  4. Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed publisher
  5. Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735 pubmed publisher
  6. Lafont E, Kantari Mimoun C, Dráber P, De Miguel D, Hartwig T, Reichert M, et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J. 2017;36:1147-1166 pubmed publisher
  7. Iurlaro R, Püschel F, León Annicchiarico C, O Connor H, Martin S, Palou Gramón D, et al. Glucose Deprivation Induces ATF4-Mediated Apoptosis through TRAIL Death Receptors. Mol Cell Biol. 2017;37: pubmed publisher
  8. Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, et al. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol Cell. 2017;65:730-742.e5 pubmed publisher
  9. Dimberg L, Towers C, Behbakht K, Hotz T, Kim J, Fosmire S, et al. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017;15:382-394 pubmed publisher
  10. Dufour F, Rattier T, Constantinescu A, Zischler L, Morlé A, Ben Mabrouk H, et al. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. Oncotarget. 2017;8:9974-9985 pubmed publisher
  11. Seo B, Min K, Woo S, Choe M, Choi K, Lee Y, et al. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP. Antioxid Redox Signal. 2017;27:215-233 pubmed publisher
  12. Park S, Jwa E, Shin S, Ju E, Park I, Pak J, et al. Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage. Int J Biochem Cell Biol. 2017;83:47-55 pubmed publisher
  13. Greene L, Nathwani S, Zisterer D. Inhibition of ?-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5. Oncol Lett. 2016;12:2900-2905 pubmed
  14. Weyhenmeyer B, Noonan J, Würstle M, Lincoln F, Johnston G, Rehm M, et al. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget. 2016;7:61295-61311 pubmed publisher
  15. Belov L, Matic K, Hallal S, Best O, Mulligan S, Christopherson R. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J Extracell Vesicles. 2016;5:25355 pubmed publisher
  16. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed publisher
  17. Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, et al. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol. 2016;16:17 pubmed publisher
  18. Crowder R, Dicker D, El Deiry W. The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. J Biol Chem. 2016;291:5960-70 pubmed publisher
  19. Yang B, Zhang M, Gao J, Li J, Fan L, Xiang G, et al. Small molecule RL71 targets SERCA2 at a novel site in the treatment of human colorectal cancer. Oncotarget. 2015;6:37613-25 pubmed publisher
  20. Zhang L, Wang H, Ding K, Xu J. FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells. Toxicol Lett. 2015;236:43-59 pubmed publisher
  21. Braun F, Mathur R, Sehgal L, Wilkie Grantham R, Chandra J, Berkova Z, et al. Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis. PLoS ONE. 2015;10:e0117994 pubmed publisher
  22. Morlé A, Garrido C, Micheau O. Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion. Cell Death Dis. 2015;6:e1633 pubmed publisher
  23. Iwaniuk A, Jabłońska E, Jabłoński J, Ratajczak Wrona W, Garley M. Expression of selected proteins of the extrinsic and intrinsic pathways of apoptosis in human leukocytes exposed to N-nitrosodimethylamine. Hum Exp Toxicol. 2015;34:591-600 pubmed publisher
  24. Sullivan E, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, et al. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res. 2014;20:5986-94 pubmed publisher
  25. Labovsky V, Martinez L, Davies K, Garcia Rivello H, Calcagno M, Matas A, et al. Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells. Clin Breast Cancer. 2015;15:e13-21 pubmed publisher
  26. Pavet V, Shlyakhtina Y, He T, Ceschin D, Kohonen P, Perala M, et al. Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells. Cell Death Dis. 2014;5:e1043 pubmed publisher
  27. Meijer A, Kruyt F, van der Zee A, Hollema H, Le P, Ten Hoor K, et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer. 2013;109:2685-95 pubmed publisher
  28. Linderoth E, Pilia G, Mahajan N, Ferby I. Activated Cdc42-associated kinase 1 (Ack1) is required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor recruitment to lipid rafts and induction of cell death. J Biol Chem. 2013;288:32922-31 pubmed publisher
  29. Lee D, Lee C, Kim D, Ae J, Lee T. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin. Anticancer Drugs. 2014;25:44-52 pubmed publisher
  30. Chen J, Shen H, Rivera Rosado L, Zhang Y, Di X, Zhang B. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget. 2012;3:833-42 pubmed
  31. Garimella S, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res. 2012;10:75-85 pubmed publisher
  32. Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem. 2011;286:43123-33 pubmed publisher
  33. Yoldas B, Ozer C, Ozen O, Canpolat T, Dogan I, Griffith T, et al. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. Head Neck. 2011;33:1278-84 pubmed publisher
  34. Son J, Varadarajan S, Bratton S. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ. 2010;17:1288-301 pubmed publisher
  35. Koschny R, Holland H, Sykora J, Erdal H, Krupp W, Bauer M, et al. Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis. J Neurooncol. 2010;97:171-85 pubmed publisher